Earnings Insights · RXRX · Q3 FY2026

Recursion Q3 2026 Earnings: Clinical Progress and Financing Extend Runway Into 2029

By AlgovestIQ ResearchPublished

Share

Read Recursion Pharmaceuticals’s results announcement (Form 8-K, filed Nov 2, 2026)

Key earnings findings

Recursion Pharmaceuticals (RXRX) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. Recursion Pharmaceuticals reported Q3 FY2026 revenue of $18.6M against the $14.8M analyst estimate, a 25.3% beat, and EPS of -$0.22 against the -$0.22 analyst estimate, 0.5% below it.
  2. Recursion reiterated its 2026 cash operating expense guidance of less than $375M, excluding partnership inflows and one-time expenses.
  3. RXRX closed at $3.68 on Nov 3, 2026, down 3.9% from $3.83 on Nov 2, 2026, the last close before the results were released.

Sources: Recursion Pharmaceuticals results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Recursion Pharmaceuticals beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$18.6M
$14.8M
+25.3%
EPS
-$0.22
-$0.22
-0.5%
  • Revenue surprise across the last 8 reported quarters has ranged from -78.9% to 44.0%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

Recursion reported Q3 revenue of $18.6M, up from $5.2M a year earlier, while its GAAP net loss narrowed to $119.0M, or $0.22 per share, from $162.3M, or $0.36 per share. The financial improvement was supported by lower operating costs and a $10M Sanofi milestone, but the more consequential development was clinical: REC-4881 produced further Phase 2 evidence of polyp-burden reduction in familial adenomatous polyposis, or FAP.

The company also raised approximately $187.2M in net proceeds through an October follow-on offering, extending its projected cash runway into 2029. For investors, the central question is whether Recursion can convert encouraging but early clinical data in REC-4881 and REC-1245 into registrational progress while sustaining its lower operating-cost base.

Earnings Snapshot

MetricReportedChange
Total revenue$18.6MUp from $5.2M
Operating revenue$18.1MUp from $5.0M
R&D expense$99.1MDown from $121.1M
G&A expense$32.6MDown from $41.6M
Loss from operations$123.2MImproved from $(172.2)M
Net loss$(119.0)MImproved from $(162.3)M
GAAP loss per share$(0.22)Improved from $(0.36)
Net cash used in operations$(77.4)MImproved from $(117.4)M
Cash, cash equivalents and restricted cash at Sept. 30$561.5MDown from $667.1M year earlier
Pro forma cash including October offering proceeds$748.7M—
Nine-month cash operating expense*$271.5MDown from $323.2M

\*Non-GAAP measure defined by the company as net cash used in operations excluding partnership inflows and certain transaction costs.

The Bigger Story

Recursion’s quarter was primarily about de-risking its clinical and financial timelines rather than near-term revenue growth. The company reported expanded Phase 2 data for REC-4881 in FAP, a rare inherited disorder that causes recurring gastrointestinal polyps and can lead to repeated surgeries and cancer risk. There are currently no approved drug therapies for FAP.

The updated data showed reductions in total polyp burden, including in the upper gastrointestinal tract and among larger polyps that may be more clinically consequential. However, the dataset remains small, and REC-4881 is not expected to enter a registrational study until the second half of 2027, pending discussions with the FDA.

The financing removes a near-term liquidity concern. But it also reinforces the nature of Recursion’s investment case: value creation will depend far more on clinical validation and partnered-program advancement than on recurring commercial revenue.

Revenue and Operating Performance

Revenue rose to $18.6M from $5.2M in the prior-year quarter. The principal driver was a $10M milestone earned from Sanofi after the pharmaceutical company optioned the first development candidate from the companies’ immunology collaboration.

That milestone improves the quarter’s reported revenue but should not be treated as recurring operating revenue. Recursion remains a clinical-stage company whose revenue is primarily generated through collaboration agreements, milestone payments and grants rather than product sales.

Sanofi’s option is strategically important beyond the immediate payment. Sanofi will lead and fund further development and commercialization of the oral small-molecule immunology candidate, which is expected to enter Phase 1 testing in 2027. Recursion said it has now received $144M in upfront and milestone payments from Sanofi and remains eligible for more than $300M in additional milestone payments under that program, plus double-digit royalties if a product is approved.

Recursion also said Genentech exercised its first validated-target option under the companies’ neuroscience collaboration. The target has moved into early discovery, with the partners now working on small-molecule design. The company has received $216M in upfront and milestone payments from its Roche and Genentech relationship to date.

These partnership advances support management’s claim that the platform can generate external-development candidates and targets. Still, most of the potential economics remain contingent on partner decisions, clinical progress and eventual regulatory success.

Clinical Pipeline Progress

REC-4881 was the quarter’s most important internal pipeline update. In the ongoing Phase 1b/2 TUPELO study in adults with FAP, 13 of 15 evaluable patients, or 87%, had a reduction in total polyp burden after 12 weeks of treatment with 4 mg once daily. The median reduction was 47%, and about one-third of patients achieved reductions of at least 65%.

The results also extended to areas that could matter most in clinical practice. In the upper GI tract, where disease may be more difficult to manage after colectomy, 12 of 13 patients had reduced polyp burden after 12 weeks, with a 55% median reduction. Two patients achieved reductions of at least 98%. In the lower GI tract, nine of 11 evaluable patients had reductions, with a 50% median decrease.

Recursion also highlighted results in larger polyps, defined as more than 5 mm. Six of eight patients with such polyps at baseline had fewer after 12 weeks, including four with reductions of at least 80%. Two patients saw larger-polyp counts fall from more than 90 to one.

The durability signal is encouraging but preliminary. Twelve weeks after treatment stopped, 11 of 13 evaluable patients remained below baseline total polyp burden. Management said this could support future exploration of dosing flexibility, though the appropriate regimen and clinical significance will need to be established in later studies.

Safety will remain an important consideration because FAP management could require chronic or intermittent treatment. Among 26 safety-evaluable patients, 81% had Grade 1 or 2 treatment-related adverse events, while four patients had Grade 3 events. There were no Grade 4 or 5 treatment-related adverse events and no additional discontinuations since the prior data cutoff. Four patients had discontinued treatment due to Grade 1 or 2 events overall, including diarrhea and rash.

REC-1245, Recursion’s oral molecular-glue program targeting RBM39, also showed early activity in heavily pretreated cancer patients. At doses of 45 mg or above, the company reported two confirmed partial responses in endometrial cancer, one unconfirmed partial response in hepatocellular carcinoma and disease control in 11 of 12 response-evaluable patients at eight weeks.

Management selected 45 mg once daily for exploratory expansion cohorts after reporting no dose-limiting toxicities or treatment-related serious adverse events at that dose. The company expects preliminary endometrial-cancer expansion data in the second half of 2027. The small patient population and early dose-escalation setting mean the data are hypothesis-generating rather than proof of a durable clinical profile.

Profitability and Margins

Recursion’s net loss narrowed by $43.2M year over year to $119.0M. The improvement reflected higher collaboration revenue and lower operating expenses.

R&D expense fell 18% to $99.1M. The largest driver was the absence of $22.8M in in-process R&D expense recorded in the prior-year period related to Recursion’s acquisition of full rights to REC-102, its ENPP1 inhibitor for hypophosphatasia, from the Rallybio joint venture. That means a meaningful portion of the year-over-year R&D decline reflects a non-recurring prior-year charge rather than solely an ongoing reduction in research activity.

G&A expense declined 22% to $32.6M, driven by lower infrastructure technology and professional-services costs. Cost of revenue also fell to $10.0M from $14.7M.

The company remains materially loss-making and does not yet have product revenue to provide operating leverage. Cost discipline is therefore most relevant as a means of extending the development runway, not as evidence of near-term profitability.

Demand, Customers and Pricing

Recursion does not have conventional product demand, volume or pricing metrics because it remains pre-commercial. The more relevant indicators are progress in its partnership portfolio and clinical pipeline.

Management said the company has generated more than $535M in cumulative cash inflows from partners and achieved nine partnership milestones over roughly two years. The Sanofi option and Genentech target advancement add evidence that partners continue to fund and advance programs originating from Recursion’s platform.

That said, these programs are still early. The future milestone and royalty streams cited by management depend on development candidate progression, clinical outcomes, regulatory approvals and commercial execution by partners.

What Is Recursion’s 2026 and 2027 Guidance?

Recursion reiterated its 2026 cash operating expense guidance of less than $375M, excluding partnership inflows and one-time expenses. Management also introduced 2027 cash operating expense guidance of less than $360M.

Management expects its cash runway to extend into 2029, based on current operating plans and without additional financing. That projection includes approximately $187.2M in net proceeds from the underwritten October follow-on offering.

For the pipeline, management expects to initiate a REC-4881 registrational trial in the second half of 2027, subject to ongoing FDA discussions. It also expects preliminary REC-1245 expansion-cohort data in the second half of 2027, while Sanofi’s optioned immunology candidate is expected to enter Phase 1 in 2027.

Balance Sheet, Cash Flow and Capital

Cash, cash equivalents and restricted cash totaled $561.5M at September 30. Including the October offering, pro forma cash was approximately $748.7M, before the additional $10M Sanofi milestone referenced by management.

Net cash used in operating activities improved to $77.4M from $117.4M in the prior-year quarter. For the first nine months of 2026, operating cash use totaled $264.5M, compared with $325.7M a year earlier.

The October financing materially strengthened liquidity, but it also increased the company’s equity base. Weighted-average shares outstanding rose to 543.0 million in Q3 from 447.0 million in the prior-year quarter, contributing to the lower per-share loss alongside the reduced absolute net loss.

What Investors Should Watch

1. REC-4881’s FDA Path and Registrational Trial Design

The next major question is whether Recursion can align with the FDA on an endpoint and study design that translates polyp-burden reductions into a viable registrational path. Management has targeted a trial start in the second half of 2027, but the timeline remains dependent on regulatory discussions.

2. Durability and Safety of REC-4881

The early off-treatment durability data are potentially differentiated, particularly if they ultimately support intermittent dosing. Investors should watch whether later data confirm sustained polyp reduction and whether rash, diarrhea, creatine phosphokinase elevations and other MEK-inhibitor-related risks remain manageable in a chronic-use setting.

3. REC-1245 Expansion Data

The two confirmed responses in endometrial cancer are encouraging but came from a small Phase 1 dataset. The 2027 expansion data will be more informative on response durability, safety at 45 mg and the program’s position relative to other late-line endometrial cancer treatments.

4. Partnership Milestones and Revenue Quality

Sanofi and Genentech activity validates Recursion’s partnering strategy, but collaboration revenue will likely remain uneven and milestone-driven. Additional development-candidate options or target advances would provide evidence that the platform can repeat its output across programs.

5. Cash Discipline After the Offering

The extended runway gives Recursion time to reach several clinical milestones. Maintaining cash operating expense below $375M in 2026 and below $360M in 2027 will be important in determining whether the company can fund its pipeline without returning to equity markets sooner than management expects.

AlgovestIQ Takeaway

Recursion entered the quarter with a clearer financial runway and stronger clinical support for its two leading internal programs. The $18.6M revenue result was boosted by a discrete Sanofi milestone, while lower R&D and G&A spending narrowed the loss and reduced operating cash use.

REC-4881 is now the most important asset in the portfolio. The updated FAP data show broad polyp-burden reductions, including upper-GI and larger-polyps results that may matter clinically if confirmed in a larger, controlled setting. The key limitation is that the data remain early, small and based on a surrogate measure rather than demonstrated reductions in surgeries, cancer risk or other long-term outcomes.

REC-1245 provides a second clinical opportunity, with early evidence of monotherapy activity in heavily pretreated patients. But the program is earlier still, and the expansion cohorts will need to show that the initial responses can be reproduced in a defined patient population at a tolerable dose.

The financing improves the company’s ability to pursue those answers. The central investment question has shifted from near-term liquidity toward execution: whether Recursion can turn promising clinical signals and partner validation into registrational progress, repeatable platform output and eventually durable value beyond collaboration milestones.

How did RXRX stock react?

RXRX closed at $3.68 on Nov 3, 2026, down 3.9% from $3.83 on Nov 2, 2026, the last close before the results were released.

SessionCloseChange
Nov 2, 2026 (before release)$3.83—
Nov 3, 2026$3.68-3.9%
Nov 4, 2026$3.88+1.3%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: Recursion Pharmaceuticals Q3 FY2026 earnings call transcript, as of Nov 3, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: Recursion Pharmaceuticals Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 2, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 3, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.